dabozza is right to point out how the design of the performance rights are not in shareholder interests. You are getting a perverse situation whereby a reduction of $0.5m of adjusted EBITDA (on my figures - it looks like dabozza's number would be a little higher given their calculation of performance rights to be issued) would drop below the 70% EBITDA target and result in the issuance of no performance rights. Bizarrely that seems like a better outcome than the likely issuance of $1.5-$1.8m in performance rights.
I don't think this is a particularly strong Board. I've seen a few things that have annoyed me and I wrote to them after they did a placement to Capital H at the current share price and announced the PFAS results in the same announcement, which obviously immediately led to a rerate. Fortunately I do rate the CEO. He is driving the turnaround in this company. I just hope the spoils of that are shared with us.
- Forums
- ASX - By Stock
- EGL
- Ann: EGL Trading Update
Ann: EGL Trading Update, page-6
Featured News
Add EGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
27.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $102.7M |
Open | High | Low | Value | Volume |
28.0¢ | 28.0¢ | 27.0¢ | $207.0K | 750.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 86071 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 72272 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 86071 | 0.270 |
9 | 214257 | 0.265 |
9 | 187869 | 0.260 |
3 | 33000 | 0.255 |
7 | 496000 | 0.250 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 72272 | 2 |
0.285 | 17562 | 1 |
0.290 | 53800 | 2 |
0.295 | 28116 | 1 |
0.300 | 42499 | 5 |
Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
Featured News
EGL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online